OBSAH

EDITORIAL ................................................................................................................................................ 1

OBSAH ....................................................................................................................................................... 2

PROGRAM ............................................................................................................................................. 4

ODBORNÁ SYMPOZIA ...................................................................................................................... 9

Sympozium Společnosti pro biologickou psychiatrii: Klozapin v současné klinické praxi ........................... 9

Má koncept neurodiverzity své místo v psychiatrii? .................................................................................. 10

Olanzapin: klinický manuál pro praxi ......................................................................................................... 11

Ketaminem asistovaná psychoterapie (KAP) v ambulantní psychiatrické praxi ........................................ 12

Sympozium Psychiatrické společnosti ČLS JEP: Psychiatrie a společnost pod tlakem ........................... 13

Neinvazivní mozková stimulace (NIBS) v české psychiatrii: Klinická praxe a nové přístupy .................... 14

Možnosti léčby neuropsychiatrických příznaků demence ......................................................................... 16

Od vzniku poruch příjmu potravy k chronicitě, od farmakoterapie k psychoterapii ................................... 17

Sympozium Národního ústavu duševního zdraví ..................................................................................... 19

Výzkum kmenových buněk a organoidů mozku u neuropsychiatrických poruch ...................................... 21

Psychedelika, problémové děti psychofarmakologie VI – translační a preklinické studie ......................... 23

Farmakodetektivky 3 ................................................................................................................................. 24

Neurobiologie spánku u ADHD ................................................................................................................. 25

Psychedelika, problémové děti psychofarmakologie VI: Od klinických studií
ke klinickým vodítkům ............................................................................................................................... 25

NOVÝ VÝZKUM .................................................................................................................................. 27

CYPRI: nástroj pro identifikaci pacientů vhodných k farmakogenetickému vyšetření
v psychiatrii ............................................................................................................................................... 27

Roční výsledky po 7týdenním ústavním programu léčby závislosti u pacientů
se závislostí na alkoholu ........................................................................................................................... 27

Vizuální kognitivní evokované potenciály u akutně hospitalizovaných se schizofrenií ............................. 27

Efekt podání 5-MeO-DMT: terénní EEG studie u zdravých dobrovolníků ................................................. 28

Propustnost střeva a imunitní aktivace u psychózy: Korelační studie u pacientů
s první epizodou a zdravých kontrol ......................................................................................................... 28

Dynamika subjektivních příznaků a objektivních parametrů (aktivita/spánek)
v okolí relapsu bipolární poruchy .............................................................................................................. 29

Riziko žilního tromboembolismu při terapii antipsychotiky a antidepresivy – analýza
z registru RIETE ....................................................................................................................................... 29

VÝVĚSKOVÁ SDĚLENÍ .................................................................................................................. 30

Klinická K1–K14 ....................................................................................................................................... 30

Preklinická P1–P5 .................................................................................................................................... 35

WORKSHOPY ..................................................................................................................................... 37

Deeskalace – základní intervence ke zvládaní agitovanosti a násilí ........................................................ 37

Algoritmus podávání off-label racemického ketaminu v psychiatrii .......................................................... 37

Pohádky 1000+1 noci (Vol. 2): Interaktivně pojaté kazuistické střípky
z psychedelických sezení u klientů s úzkostně-depresivním spektrem obtíží
v rámci ketaminem asistované psychoterapie na klinice Psyon ............................................................... 37

Psilocybin v klinické praxi – zkušenosti z klinických studií nejen z ČR ..................................................... 37

VOLNÁ SDĚLENÍ .............................................................................................................................. 38

Psychiatrické komplikace v onkologii ....................................................................................................... 38

Úloha fytoterapie v současné farmakoterapii a prevenci poruch nervového systému
a psychických poruch ............................................................................................................................... 38

Konopí pro léčebné využití v terapii nervových poruch a bolesti .............................................................. 38

Je editovanie génov budúcnosťou psychofarmakológie? ......................................................................... 39

REJSTŘÍK ................................................................................................................................................ 40

CONTENTS

EDITORIAL ................................................................................................................................................ 1

CONTENTS ............................................................................................................................................... 2

PROGRAM ............................................................................................................................................ 4

SCIENTIFIC SYMPOSIA .................................................................................................................. 9

Symposium of the Czech Society for Biological Psychiatry: Clozapine in current
clinical practice ......................................................................................................................................... 9

Is there a place for the neurodiversity concept in psychiatry? ................................................................ 10

Olanzapine: a clinical practice manual .................................................................................................... 11

Ketamine-assisted psychotherapy (KAP) in outpatient psychiatry .......................................................... 12

Symposium of the Czech Psychiatric Association: Psychiatry and society under pressure .................... 13

Non-invasive brain stimulation (NIBS) in Czech psychiatry: clinical practice
and new approaches ............................................................................................................................... 14

Management of neuropsychiatric symptoms of dementia ....................................................................... 16

From the onset of eating disorders to chronicity, from pharmacotherapy to psychotherapy .................... 17

Symposium of the National Institute of Mental Health ............................................................................. 19

Stem cell and brain organoid research in neuropsychiatric disorders ...................................................... 21

Psychedelics, problem children of psychopharmacology VI – translational
and preclinical studies .............................................................................................................................. 23

Psychopharmac detective stories 3rd ...................................................................................................... 24

Neurobiology of sleep in ADHD ............................................................................................................... 25

Psychedelics, problem children of psychopharmacology VI: From clinical trials
to clinical guidelines ................................................................................................................................. 25

NEW RESEARCH ............................................................................................................................. 27

CYPRI: a tool for identifying patients suitable for pharmacogenetic testing in psychiatry ....................... 27

One-year outcomes after a 7-week inpatient addiction treatment program: analysis
of patients with alcohol use disorder ....................................................................................................... 27

Visual cognitive evoked potentials in acutely hospitalized patients with schizophrenia ......................... 27

Effect of administration on 5-MeO-DMT; an EEG field study in healthy volunteers ............................... 28

Gut permeability and immune activation in psychosis: a correlation study
in first-episode patients and healthy controls ......................................................................................... 28

Dynamics of self-reported symptoms and objective parameters (aktivity/sleep)
around bipolar disorder relapse ............................................................................................................. 29

Risk of venous thromboembolism in patients treated with antipsychotics
and antidepressants – analysis from the RIETE registry ....................................................................... 29

POSTERS .......................................................................................................................................... 30

Clinical K1–K14 ..................................................................................................................................... 30

Preclinical P1–P5 .................................................................................................................................. 35

WORKSHOPS .................................................................................................................................. 37

Deescalation – basic interventions for coping with aggression and violence ........................................ 37

Algorithm for off-label use of ketamine in psychiatry ............................................................................. 37

One thousand and one nights tales (Vol. 2): Case vignettes from psychedelic sessions

in anxiety and depression spectrum disorders within ketamine-assisted psychotherapy
at Psyon Clinic ....................................................................................................................................... 37

Psilocybin in clinical practice – experiences from clinical studies not limited
to the Czech Republic ............................................................................................................................ 37

FREE COMMUNICATIONS .......................................................................................................... 38

Psychiatric complications in oncology .................................................................................................... 38

The role of phytotherapy in contemporary pharmacotherapy and prevention
of nervous system disorders and mental disorders ................................................................................ 38

Cannabis for medicinal use in the treatment of nervous disorders and pain .......................................... 38

Is gene editing the future of psychopharmacology? ............................................................................... 39

INDEX........................................................................................................................... 40